Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1649 1675
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18222093 | Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodies | Non-Final OA | Janssen Biotech, Inc. |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18037243 | CHIMERIC ANTI-HUMAN BRAF V600E ANTIBODIES AND METHODS FOR MAKING AND USING THEM | Non-Final OA | Agilent Technologies, Inc. |
| 18670375 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Final Rejection | Hoffmann-La Roche Inc. |
| 17785427 | BIFUNCTIONAL MOLECULES COMPRISING AN IL-7 VARIANT | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy